FDA Sets Review Period for UNLOXCYT Patent Extension
Published Date: 4/16/2026
Notice
Summary
The FDA has set the official review period for UNLOXCYT, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind UNLOXCYT and anyone interested in patent timing or drug development. If you think the dates are wrong or want to challenge the company’s diligence, you have until mid-2026 to speak up—potentially impacting patent length and market exclusivity.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Sets 2,000-Day Review Period
If you are the patent holder or work for the company behind UNLOXCYT, FDA has officially determined the regulatory review period is 2,000 days (1,289 days testing phase and 711 days approval phase). This determination establishes the maximum potential length of a patent extension; the applicant (Checkpoint Therapeutics, Inc.) seeks 196 days of patent term extension.
Deadlines to Challenge Dates or Diligence
If you believe any published dates are wrong, you must submit comments asking for a redetermination by June 15, 2026. If you want FDA to decide whether the applicant acted with due diligence during the review period, you may file a petition by October 13, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in